A compound is expected to reduce muscle movement problems in Parkinson's patients

A new study by the Texas Biomedical Research Institute (Texas Biomedical Research Institute, Texas Biomed) and its collaborators has discovered a promising drug candidate that can reduce the uncontrolled, Unstable muscle movement, that is, dyskinesia

This small molecule, called PD13R, reduces dyskinesia by more than 85% in the marmoset animal model of Parkinson's disease

Dyskinesia is a common side effect in patients with Parkinson's disease

"Levodopa is magical.

Designing drugs to treat Parkinson's disease and its side effects is notoriously difficult

In order to identify a compound that only binds to dopamine receptor #3 (D3), Daadi collaborated with the Southwest Research Institute

Daadi and his team at the Texas Biomedical Center explored how the compound targets the D3 receptor in cell culture tests compared to other dopamine receptors

The research team then injected PD13R into the marmoset model of Parkinson's disease

Daadi explained: "We are very excited to see the drug's powerful anti-dyskinesia effect

These animals wear activity monitors and use PD13R.

Daadi and his team plan to continue the safety and efficacy studies required by the U.

Article title

Dopamine D3 receptor ligand inhibits the expression of levodopa-induced dyskinesia in a non-human primate model of Parkinson’s disease